Gerami, PedramCook, Robert W.Russell, Maria C.Wilkinson, JeffAmaria, Rodabe N.Gonzalez, ReneLyle, StephenJackson, Gilchrist L.Greisinger, Anthony J.Johnson, Clare E.Oelschlager, Kristen M.Stone, John F.Maetzold, Derek J.Ferris, Laura K.Wayne, Jeffrey D.Cooper, ChelseaObregon, RoxanaDelman, Keith A.Lawson, David2022-08-232022-08-232015-05-012015-04-24J Am Acad Dermatol. 2015 May;72(5):780-785.e3. doi: 10.1016/j.jaad.2015.01.009. Epub 2015 Mar 3. <a href="http://dx.doi.org/10.1016/j.jaad.2015.01.009">Link to article on publisher's site</a>0190-9622 (Linking)10.1016/j.jaad.2015.01.00925748297https://hdl.handle.net/20.500.14038/36517BACKGROUND: A gene expression profile (GEP) test able to accurately identify risk of metastasis for patients with cutaneous melanoma has been clinically validated. OBJECTIVE: We aimed for assessment of the prognostic accuracy of GEP and sentinel lymph node biopsy (SLNB) tests, independently and in combination, in a multicenter cohort of 217 patients. METHODS: Reverse transcription polymerase chain reaction (RT-PCR) was performed to assess the expression of 31 genes from primary melanoma tumors, and SLNB outcome was determined from clinical data. Prognostic accuracy of each test was determined using Kaplan-Meier and Cox regression analysis of disease-free, distant metastasis-free, and overall survivals. RESULTS: GEP outcome was a more significant and better predictor of each end point in univariate and multivariate regression analysis, compared with SLNB (P < .0001 for all). In combination with SLNB, GEP improved prognostication. For patients with a GEP high-risk outcome and a negative SLNB result, Kaplan-Meier 5-year disease-free, distant metastasis-free, and overall survivals were 35%, 49%, and 54%, respectively. LIMITATIONS: Within the SLNB-negative cohort of patients, overall risk of metastatic events was higher ( approximately 30%) than commonly found in the general population of patients with melanoma. CONCLUSIONS: In this study cohort, GEP was an objective tool that accurately predicted metastatic risk in SLNB-eligible patients. Inc. All rights reserved.en-USCancer BiologyDermatologyMolecular GeneticsNeoplasmsSkin and Connective Tissue DiseasesJournal Articlehttps://escholarship.umassmed.edu/mccb_pubs/117027656mccb_pubs/11